Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma

Xin Liu; Meng Fu; Daqing Xia; Zimei Ji; Nana Hu; Zaijun Leng; Wang Xie; Yuan Fang; Junqiang Zhang

doi:10.1155/2022/8767333

Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma

J Oncol. 2022 Oct 5:2022:8767333. doi: 10.1155/2022/8767333. eCollection 2022.

Authors

Xin Liu¹, Meng Fu^{2

3

4}, Daqing Xia², Zimei Ji², Nana Hu², Zaijun Leng², Wang Xie², Yuan Fang², Junqiang Zhang^{1

2}

Affiliations

¹ Bengbu Medical College, Bengbu, 233030 Anhui, China.
² Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
³ Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China.
⁴ University of Science and Technology of China, Hefei 230026, China.

Abstract

Family with sequence similarity 83, member A (FAM83A) plays an essential and fundamental role in the proliferation, progression, and apoptosis of many malignant tumors, including lung cancer. This study aimed to determine the expression pattern of FAM83A in lung adenocarcinoma (LUAD) and its correlation with the prognosis of cancer and the survival of the patients. Bioinformatics analysis, immunohistochemistry, and Western blotting were used to explore and detect the expression of FAM83A in LUAD cells. The mechanism of FAM83A in proliferation and migration was examined. The correlation between FAM83A expression and survival rate was assessed by the Kaplan-Meier and Cox regression. FAM83A expression was elevated in LUAD tissues and was related to shorter overall survival (P < 0.05). A significant increase in FAM83A protein was observed in the LUAD tissue (P < 0.05). Compared with patients with early-stage tumors (stage I-II), those with advanced stage tumors (stage III-IV) had significantly higher FAM83A expression levels (P < 0.05). Downregulation of FAM83A led to a reduction in cell proliferation, a decrease in migration ability, and diminished epithelial-mesenchymal transition (EMT) in the lung cancer cell lines. Overexpression of FAM83A was associated with early lymph node metastasis and poor overall survival among LUAD patients. The findings indicated that FAM83A may play a critical role in promoting the LUAD progression and thus might serve as a novel prognostic marker in LUAD.